CWI1-2 is an IGF2BP2 inhibitor. CWI1-2) shows promising anti-leukemia effects in vitro and in vivo. CWI1-2 preferentially binds to IGF2BP2 and inhibits its interaction with m6A-modified target transcripts. Targeting IGF2BP2 with CWI1-2 alone, or in combination with other agents, such as daunorubicin (DNR) or homoharringtonine (HHT), shows promising therapeutic efficacy in treating AML. CWI1-2 treatment significantly delayed leukemia onset and prolonged the survival of BMT recipient mice. Importantly, monitoring of body weight from the day of drug treatment for 12-18 days did not show any reduction of body weight upon CWI1-2 treatment. CWI1-2 is an effective and largely safe leading compound targeting IGF2BP2 for AML treatment.
MedKoo Cat#: 124228
Name: CWI1-2 HCl
CAS#: 2408590-37-2 (HCl)
Chemical Formula: C22H18Cl4N6O3
Exact Mass: 554.0194
Molecular Weight: 556.23
Elemental Analysis: C, 47.51; H, 3.26; Cl, 25.49; N, 15.11; O, 8.63
The following data is based on the product molecular weight 556.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
